Sequencing method for efficiently enriching full-length sequence of pathogenic microorganism genome
Through probe hybridization and streptavidin magnetic bead enrichment technology, the problem of the inability to obtain the full-length genome and host background interference of pathogenic microorganisms in the prior art is solved, and efficient and low-cost genome enrichment and detection of pathogenic microorganisms is achieved. .
Patent Information
- Application Number
- CN202411394821.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-08
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art cannot effectively obtain the full-length genomic sequence of pathogenic microorganisms, and there is a problem of host background interference, resulting in low detection sensitivity and high cost.
Using a targeted capture method based on probe hybridization, a host genome capture probe is designed to remove host DNA, and the pathogenic microbial genome is enriched through streptavidin magnetic beads to achieve efficient enrichment of the full-length sequence of the pathogenic microbial genome.
It improves the sensitivity and genomic coverage of pathogen detection, reduces detection cost and operational complexity, and is suitable for low-abundance samples and different host species.
Smart Images

Figure CN119020461A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of pathogenic microorganism genome sequencing, and relates to a sequencing method for efficiently enriching the full-length sequence of pathogenic microorganism genome, and in particular to a hybridization targeted capture method, probe design and application thereof. Background Art
[0002] Infections caused by pathogenic microorganisms have become a public health problem that seriously affects human health. Respiratory tract infections are a common type of clinical disease, and the main pathogenic microorganisms include viruses, bacteria, fungi, and atypical pathogens. According to the 2019 Global Health Estimates Report released by the WHO, lower respiratory tract infections ranked fourth among the top 10 causes of death in the world in 2019, causing 2.6 million deaths throughout the year; and in low-, middle-, upper-middle- and high-income countries, lower respiratory tract infections are the only infectious disease that ranks among the top 10 causes of death. In addition, due to the lack of effective means of detecting pathogenic microorganisms, especially the detection of drug-resistant genes, the abuse of antibiotics in clinical practice is very common.
[0003] Early pathogen detection methods include culture, smear microscopy, and antigen-antibody detection. These technologies generally have problems such as long cycles, poor specificity, and low sensitivity, and are very limited in clinical use. With the development of molecular diagnostic technology, detection technologies based on PCR and mNGS (metagenomic sequencing) have emerged one after another, bringing the detection of pathogenic microorganisms into the molecular era and greatly improving the clinical positive rate. However, these two methods also have certain limitations. Among them, PCR technology mainly uses primers to amplify specific regions of the target pathogen for identification. There are problems such as the inability to obtain the full length of the pathogen genome, relatively limited detection targets, and low tolerance to pathogen genome variations; although mNGS has solved some of the shortcomings of PCR technology, host background infection has always been a pain point for mNGS detection, especially for some samples with low infection abundance, there is a risk of missed detection, and a high amount of sequencing data is required, which greatly increases the detection cost.
[0004] Conventional host removal methods, such as NEB's magnetic beads selectively binding to CpG methylated host DNA and Qiagen's host cell selective lysis, have disadvantages such as high cost, high sample integrity requirements, and complex operations. Summary of the invention
[0005] The main purpose of the present invention is to provide a method for obtaining pathogenic microorganism nucleic acid by removing the host genome in the sample based on probe hybridization; and to provide a sequencing method for efficiently enriching the full-length sequence of the pathogenic microorganism genome, specifically to provide a second-generation sequencing method combining host removal with probe hybridization targeted capture. This solves the problems of the inability to obtain the full-length pathogen genome and high host background in the prior art.
[0006] The objective of the present invention is achieved through the following technical solutions:
[0007] In a first aspect, the present invention provides a method for removing host genome from a sample to obtain pathogenic microorganism nucleic acid based on probe hybridization, comprising:
[0008] S1. Design a host genome capture probe, which is a biotin-modified oligonucleotide complementary to the host genome nucleic acid base;
[0009] S2, hybridizing the total nucleic acid extracted from the pathogen sample with the host genome probe of S1;
[0010] S3, incubate with streptavidin and hybridization mixture;
[0011] S4, using a magnetic device to aggregate the magnetic beads containing the host genome;
[0012] S5. Take the supernatant to obtain the host-free nucleic acid and construct the library.
[0013] As an embodiment of the present invention, the host genome probe is designed by setting probes at intervals of 50-100 kb on the host genome to evenly cover the entire genome of the host.
[0014] As one embodiment of the present invention, the host is a human.
[0015] The host probe designed by the present invention can indiscriminately target the entire host human genome. The specific design method is to place probes at intervals of 50-100 kb on human genes to evenly cover one pair of sex chromosomes and 22 pairs of autosomes in the human genome.
[0016] The present invention utilizes a probe method to remove host DNA, which is simple to operate, low in cost, high in probe specificity, and low in sample quality requirements. Furthermore, the problem of excessive removal leading to a low detection rate can be avoided through probe design.
[0017] In a second aspect, the present invention provides a sequencing method for efficiently enriching the full-length sequence of the genome of pathogenic microorganisms, comprising:
[0018] S6. constructing a pre-library of the pathogenic microorganism nucleic acid obtained according to the above method;
[0019] S7, centrifugally concentrate the constructed pre-library, add biotin-modified pathogenic microorganism probes and hybridization mixture to perform hybridization incubation;
[0020] S8, incubating the streptavidin magnetic beads with the hybridization mixture;
[0021] S9, using a magnetic device to adsorb magnetic beads bound to pathogen genomes;
[0022] S10, performing PCR amplification on the magnetic bead suspension to obtain the enriched microbial genome;
[0023] S11. Perform library quality inspection and sequencing analysis.
[0024] As an embodiment of the present invention, the pathogenic microorganism probe in step S7 is designed based on the target pathogenic microorganism genome reference sequence using a highly shingled probe design method.
[0025] As an embodiment of the present invention, in step S7, the pathogenic microorganism probe and the prelibrary are hybridized and incubated at 60-70°C.
[0026] Preferably, the hybridization incubation temperature is 65°C.
[0027] As an embodiment of the present invention, in step S8, streptavidin is mixed with the hybridization mixture and then incubated at room temperature on a vertical rotator or an oscillating metal bath.
[0028] As an embodiment of the present invention, in step S9, the magnetic bead mixture after room temperature incubation in S8 is placed on a magnetic rack, the supernatant is discarded after rapid centrifugation, incubated and washed at 60-70°C, and the magnetic beads are resuspended with nuclease-free water, and the pathogen genome is adsorbed on the magnetic beads.
[0029] Preferably, the incubation temperature is 65°C.
[0030] As an embodiment of the present invention, step S10, after PCR amplification of the pathogen genome bound to the magnetic beads, further includes washing the magnetic beads with ethanol, eluting the pathogen genome from the magnetic beads with a buffer solution, and centrifuging on a magnetic stand, and the pathogen genome is located in the supernatant.
[0031] The present invention provides a method for targeted enrichment of full-length sequences of pathogenic microorganism genes, specifically, based on the target pathogen genome reference sequence, using highly shingled probes to design enrichment probes covering the target pathogen genome, thereby obtaining the full length of the genome while improving the uniformity of genome coverage.
[0032] Patent CN111057747A discloses a microbial nucleic acid extraction method and a kit with the function of removing host genomic DNA, which uses a primer modified with biotin at the 5' end, and obtains a probe for removing the host genome by PCR amplification. The present application uses a probe modified with biotin to be directly synthesized, and no additional probe preparation process is required. Compared with the process, the present application omits the PCR process of probe preparation, the denaturation process of double-stranded probes, and the concentration homogenization process of each probe, which is simple to operate and has lower cost. The period in which the patent is located is limited by synthesis technology, and the cost of preparing probes by primer amplification is lower than that of preparing probes by direct synthesis. However, with the advancement of synthesis technology, the cost of direct synthesis probes is now much lower than that of preparing probes by primer amplification. The early method of preparing capture probes by primer amplification is basically no longer used. In addition, compared with the PCR amplification method, the direct method does not rely on the characteristics of the template sequence, and avoids the common amplification heterogeneity problem of PCR amplification.
[0033] In addition, its probe targets multiple highly repetitive sequences in the host human genome, including the MIR family (including MIRb, MIRAC, MIRc, MIR3, etc.), the ALu family, etc., but compared to the entire human gene, the target ratio is extremely low. When the sample is subject to certain degradation during storage, transportation or extraction, most of the areas in the host human genome that are not covered by the probe will not be captured and removed by the current probe, which will seriously affect the host removal effect, making this method heavily dependent on sample quality, and samples with excellent integrity are required to obtain the expected host background removal effect. Unlike patent CN111057747A, the probes in this application indiscriminately target the entire host human genome. The specific design method is to place probes at intervals of 50-100kb on human genes, evenly covering 1 pair of sex chromosomes and 22 pairs of autosomes in the human genome. Compared with this patent, even if the clinical sample is subject to certain degradation, a relatively ideal background removal effect can still be obtained, which expands the wide application of removing the host genome by the probe method in actual clinical scenarios.
[0034] Although there are also methods of designing capture probes for the whole genome nucleic acid of the host in the prior art, such as patent CN117778525A, the method used in designing probes for capturing the whole genome nucleic acid of the host is a shingled probe design method, the length of the probe is 110-130nt or 110-130bp, and the overlapping part of adjacent probes is 40-130nt or 40-130bp. In comparison, the probe design method used in the present application is not a shingled design, but a host capture probe is designed at intervals of 50-100kb on the host genome. This method can also achieve uniform coverage of the whole genome of the host, and can also greatly reduce the number of capture probes, thereby reducing costs and making the capture operation easier.
[0035] Compared with the prior art, the present invention has the following beneficial effects:
[0036] 1) The probe host removal method of the present invention has lower sample requirements compared to other host removal methods on the market. Conventional methods need to be based on the integrity of host cells, special genome modifications (CpG methylation), etc. If the sample has problems such as cell rupture and nucleic acid degradation, the conventional method may fail; the method of the present invention is to directly design base complementary probes for host genome nucleic acids, which has strong specificity and the removal effect does not depend on the sample quality;
[0037] 2) The method of the present invention improves the sensitivity of pathogen detection by removing the host and using high-density probes; the conventional probe method captures the full length of the pathogen genome, and when the abundance of the pathogen is low (CT value>30), it is impossible to obtain a target pathogen genome sequence close to the full length (>99% genome coverage). The method of the present invention greatly improves the efficiency of targeted enrichment by removing the host. Under the same amount of sequencing data, even low-abundance samples (CT value>30) can obtain a target pathogen genome sequence close to the full length, with high sensitivity;
[0038] 3) The method of the present invention does not require a special nucleic acid extraction process, is simple to operate, and has strong repeatability;
[0039] 4) The method of the present invention is not limited to the host species category. Conventional methods cannot distinguish the host category. It is currently mainly used for human host removal. There is no host removal method for hosts other than human hosts. The present invention can design specific probes according to different hosts, which is independent of the host species category and has a wide applicability;
[0040] 5) The method of the present invention designs host capture probes at intervals of 50-100 kb on the host genome, which can achieve uniform coverage of the entire host genome and greatly reduce the number of capture probes. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Other features, objects and advantages of the present invention will become more apparent from the detailed description of non-limiting embodiments made with reference to the following drawings:
[0042] Figure 1 This is a schematic diagram of the enrichment effect of Example 1 of the present invention on high-risk HPV virus type HPV16;
[0043] Figure 2 This is a schematic diagram of the enrichment effect of Example 1 of the present invention on the HPV18 high-risk HPV virus genome. DETAILED DESCRIPTION
[0044] The present invention is described in detail below in conjunction with embodiments. The following embodiments will help those skilled in the art to further understand the present invention, but are not intended to limit the present invention in any form. It should be noted that, for those of ordinary skill in the art, some adjustments and improvements can also be made without departing from the concept of the present invention. These all belong to the protection scope of the present invention.
[0045] The method of the present invention and the conventional probe enrichment method on the market (without removing the host) were set as Example 1 and Comparative Example 1, respectively, and the enrichment of two high-risk HPV genomes, HPV16 / 18, was compared.
[0046] Source of materials: HPV samples were purchased from GeneWell (Shenzhen), product number: GW-IPF001 (HPV16) and GW-IPF002 (HPV18); human wild-type genomic gDNA was purchased from GeneWell (Shenzhen), product name NA12878, product number: GW-SHF001.
[0047] Take 10 HPV16 and 10 HPV18 samples each 4 The copies were mixed with 100 ng of human wild-type genomic gDNA (GeneWell, NA12878, GW-SHF001) to simulate clinical samples and prepared into HPV nucleic acid samples for testing.
[0048] The HPV RNA probe design method is as follows:
[0049] The reference sequences of HPV16 / 18 are NCBI RefSeq assembly, GCF_000863945.3 / GCF_000865665.1. The design method is to download the full-length reference sequence of HPV16 / 18 from the NCBI database, use commercial bioinformatics probe design software (Agilent, SureDesign) to design probes, and purchase the probes and matching capture reagents from a commercial probe synthesis company (Dynegene).
[0050] The host RNA probe design method is as follows:
[0051] The host-removal probes refer to the human genome version GRCh37, and the coverage probes are set at intervals of 50 kb on the human genome. The probe length is 120 bp and is used for capturing and removing the host genome. The probes are designed using commercial bioinformatics probe design software (Agilent, SureDesign), and the matching capture reagents are purchased from a commercial company (Dynegene).
[0052] Example 1: Enrichment of two high-risk HPV types HPV16 / 18 using the method of the present invention
[0053] 1. Removal of host genome
[0054] 1.1 Take 100 ng of pre-mixed nucleic acid sample in a 0.2 ml PCR centrifuge tube, including HPV16 / 18 and host human gDNA, and mix with the hybridization system shown in Table 1. Other reagents are purchased from a commercial company (Dynegene, NC1003A).
[0055] Table 1 Hybridization system
[0056]
[0057]
[0058] 1.2 Perform hybridization reaction on the PCR instrument according to the following procedure in Table 2:
[0059] Table 2 Hybridization reaction procedures
[0060] step Temperature(℃) time 1 95 30s 2 65 16h
[0061] 1.3 After the hybridization reaction is completed, add 50ul of washed streptavidin magnetic beads to the reaction system and incubate at room temperature for 30 minutes.
[0062] 1.4 After the incubation, shake and mix the PCR tube, centrifuge it, and place it on a magnetic rack. After the solution is clarified, take the supernatant into another new 0.2ml PCR centrifuge tube. This supernatant contains the HPV genome, which is used for subsequent library construction and sequencing, while the host enrichment on the magnetic beads is removed.
[0063] 1.5 Use a commercially available universal library construction kit (Dynegene, NL1002A) to construct a pre-library, and use HPV enrichment probes for targeted enrichment.
[0064] 2. Sample and Probe Hybridization
[0065] 2.1 Take 500 ng of the HPV pre-library constructed in 1.5 and put it into a new PCR tube. Place the centrifuge tube into a centrifugal concentrator. Open the PCR tube cover, start the centrifugal concentrator, and start concentrating.
[0066] Depending on the type of centrifugal concentrator, the drying time is 5-15 minutes, so please pay attention to the observation. After drying, add 5 μL of nuclease-free water and shake thoroughly, centrifuge and let stand for later use.
[0067] 2.2 Take a new 1.5mL centrifuge tube or 0.2mL PCR tube and place it on a room temperature tube rack to prepare the hybridization mixture according to the system shown in Table 3.
[0068] Table 3 PCR system
[0069]
[0070]
[0071] The HPV RNA probes in the above table are modified with biotin.
[0072] 2.3 Add the prepared hybridization mixture to the 5 μL pre-library in step 2.1, and use a pipette to gently pipette and mix 8 times (note that during the pipetting process, press the pipette down to about 2 / 3 of the liquid collection range and then release it, repeat 8 times to avoid pressing it all the way to the bottom to produce bubbles).
[0073] Seal with a tube cap or 96-well plate sealing film, and centrifuge quickly for 5 seconds. Place the pre-library hybridization mixture on the PCR instrument for hybridization. Set the following PCR program, hot cover mode (105°C), set the volume to 40μL (total hybridization volume 36μL), start the run, and hybridize overnight at 65°C for 16 hours. The hybridization reaction program is shown in Table 4.
[0074] Table 4 PCR hybridization reaction program
[0075] step Temperature(℃) time 1 95 30s 2 65 Keep
[0076] 3. Preparation of Streptavidin Magnetic Beads
[0077] 3.1 Before capture, take out the streptavidin magnetic beads from the 4℃ refrigerator, shake on a vortex shaker for 30 seconds until the beads are fully resuspended, and then equilibrate at room temperature for more than 30 minutes. After equilibration at room temperature for more than 30 minutes, shake the streptavidin magnetic beads on a vortex shaker for 30 seconds to resuspend, and add 50μL of streptavidin magnetic beads to each well of the 8-tube strip, paying attention to adding to the bottom of the tube to avoid staining the tube wall and tube cover.
[0078] 3.2 Then add 150 μL of Wash Buffer 1 (Dynegene, NC1003A) to each well and gently pipette 8 times with an 8-row pipette to mix the magnetic beads thoroughly. Place on a magnetic stand and let stand to clarify, then discard the supernatant. If the tube wall or tube cover is stained with magnetic beads, quickly centrifuge for 5 seconds to shake them to the bottom of the tube.
[0079] 3.3 Repeat step 3.2 for a total of 3 washes with Wash Buffer 1 (Dynegene, NC1003A). Finally, aspirate the supernatant and leave only the magnetic beads at the bottom of the tube.
[0080] 3.4 Finally, add 150 μL of Wash Buffer 1 (Dynegene, NC1003A) to each well to resuspend the magnetic beads, mark the corresponding hybridization sample name on each well, and place it at room temperature for use.
[0081] 4. Capture magnetic beads to enrich the library and wash
[0082] 4.1 After the hybridization mixture is incubated at 65℃ for 16 hours, ensure that the remaining hybridization system volume is not less than 20μL. Open the PCR tube on the PCR instrument, add 150μL of the magnetic bead resuspension solution in step 2.4 to the hybridization mixture with a pipette, and gently pipette 8 times.
[0083] Then transfer all the mixed solution containing magnetic beads and hybridization system to the 8-tube magnetic beads marked in step 3.4. Note that the marks on the hybridization tube and the marks on the magnetic beads tube need to correspond one to one. Be careful not to remove the hybridization mixture from the PCR instrument. The drop in temperature will lead to a decrease in capture efficiency.
[0084] 4.2 Remove the magnetic bead hybridization mixture from the PCR instrument and place it on a vertical rotator and fix it. Rotate and incubate at room temperature for 30 minutes. You can also use a shaking metal bath and set it to 1000-1500r / min for room temperature shaking incubation. After removing the hybridization mixture, do not turn off the PCR and maintain 65°C. Wash Buffer 3 (Dynegene, NC1003A) is required for incubation and cleaning in the subsequent steps.
[0085] 4.3 After 30 minutes, remove the 8-tube strip from the rotator or shaking metal bath, centrifuge quickly for 5 seconds, place on the magnetic rack for 2-5 minutes to ensure that the liquid is clear, and discard the supernatant.
[0086] 4.4 Remove the 8-tube strip from the magnetic rack, add 150 μL of Wash Buffer 2 (Dynegene, NC1003A) to each well to resuspend the magnetic beads, pipette gently 10 times, incubate at room temperature for 15 minutes, and quickly invert up and down 15 times every 5 minutes.
[0087] 4.5 After incubation at room temperature with Wash Buffer 2 (Dynegene, NC1003A), centrifuge quickly for 5 seconds and place on a magnetic rack until the liquid becomes clear, then discard the supernatant and place on a 65°C hybridization PCR instrument. Immediately add 150 μL of preheated Wash Buffer 3 (Dynegene, NC1003A) using an 8-row pipette, pipette 10 times on the PCR instrument to fully mix the magnetic beads, cover the tube and incubate at 65°C for 10 minutes.
[0088] 4.6 After incubation at 65℃ for 10 minutes, remove the tube from the PCR instrument and place it on a magnetic rack. When the liquid is clear, aspirate and discard the supernatant.
[0089] 4.7 Repeat steps 4.5-4.6 and wash three times with Wash Buffer 3 (Dynegene, NC1003A).
[0090] 4.8 After three washes, centrifuge quickly for 10 seconds, place on the magnetic stand again and use a 10μL pipette to remove all residual liquid as much as possible. Finally, add 20μL of nuclease-free water to resuspend the magnetic beads, and gently pipette 8 times to mix well for later use.
[0091] 5. PCR Amplification
[0092] 5.1 On ice, use 8 tube strips to prepare the PCR amplification reaction system as shown in Table 5:
[0093] Table 5 PCR amplification reaction system
[0094] Reagent components Reaction volume (μL) PCR Mix (Dynegene, NC1003A) 25 Post-Primer Mix (Dynegene, NF2503A) 5 Total volume 30
[0095] 5.2 Adjust the volume of the 8-tube pipette to 40 μL, pipette all the magnetic bead suspension in step 4.8 and add it to the 8-tube pipette marked in step 5.1.
[0096] 5.3 Place the 8-tube strips in step 5.2 on the PCR instrument and start running the program shown in Table 6.
[0097] Table 6 PCR reaction program
[0098]
[0099] 5.4 After PCR is completed, remove the 8-tube strip, centrifuge quickly for 5 seconds, and place it on a magnetic rack. After standing for 1 minute, aspirate all the supernatant and transfer it to a new PCR tube. Then add 90 μL (1.8×) DNA purification magnetic beads equilibrated at room temperature, and pipette 8-10 times to mix thoroughly.
[0100] 5.5 Leave at room temperature for 5 minutes. During this time, prepare 80% ethanol and mix it with nuclease-free water. The estimated amount for each sample is 400 μL.
[0101] 5.6 Place on a magnetic rack and let stand for 3-5 minutes to clarify, then discard the supernatant.
[0102] 5.7 Keep the tube on the magnetic rack and do not remove it. Add 150μL of 80% ethanol and let it stand until the magnetic beads are completely adsorbed to one side. Then remove the tube from the magnetic rack and turn it 180 degrees. After the magnetic beads are completely adsorbed to the other side, turn it again. After turning it 4 times in total, aspirate and discard the supernatant.
[0103] 5.8 Repeat step 5.7.
[0104] 5.9 After rapid centrifugation, use a 10μL pipette to discard the residual ethanol and leave at room temperature for 1-3 minutes until there is no obvious liquid residue on the surface of the magnetic beads and the beads are just matte or matte.
[0105] 5.10 Remove the tube from the magnetic rack, add 20 μL of Low TE for elution, pipette 8-10 times to mix, and let stand at room temperature for 2 minutes.
[0106] 5.11 Place the tube on a magnetic rack and let it stand for clarification, then aspirate the supernatant and transfer it to a new PCR tube to complete hybridization capture and wait for library quality inspection and loading onto the machine.
[0107] 6. Library quality inspection and loading
[0108] 6.1 Library quality control: use The concentration of the library obtained by hybridization capture was detected by dsDNA HS Assay Kit, and the size of the library fragments was detected using 2100 Bioanalyzer, all in accordance with the instructions.
[0109] 6.2 The libraries that passed the quality inspection were sequenced using the BGI sequencer DNBSEQ-T7, with the sequencing mode set to PE150 (i.e., double-end sequencing, with each sequence measuring 150 bases), and 1G of sequencing data was arranged for each sample.
[0110] 7. Analysis of Sequencing Results
[0111] Figure 1 and Figure 2 The enrichment effect of Example 1 on two high-risk HPV viruses, HPV16 and HPV18, is shown respectively. Figure 1 This is the HPV16 genome enrichment effect displayed using the genome visualization software (IGV) in Example 1. It can be seen from the display effect diagram that through the method of the present invention, an HPV16 genome close to the full-length sequence (>99% genome coverage) is obtained, and the genome coverage is highly uniform. Figure 2 The enrichment effect of the HPV18 genome displayed by the genome visualization software (IGV) in Example 1 can be seen from the display effect diagram that, through the method of the present invention, a nearly full-length sequence of the HPV18 genome (>99% genome coverage) is obtained, and the genome coverage is highly uniform. Therefore, Example 1 can obtain the full-length sequence of the HPV virus genome, and the entire genome coverage is highly uniform.
[0112] Comparative Example 1: Enrichment of HPV virus genome using conventional probe enrichment method (without host removal)
[0113] Compared with Example 1, the host removal step was omitted, a commercially available universal library construction kit (Dynegene, NL1002A) was used to construct a prelibrary, and HPV enrichment probes were used for targeted enrichment. The remaining steps were consistent with Example 1.
[0114] The HPV nucleic acid samples (including HPV16 / HPV18) enriched by the enrichment methods of Example 1 and Comparative Example 1 were recorded as HPV-2 and HPV-1, respectively. The enrichment effects of HPV-1 and HPV-2 were tested and compared, and each sample was tested twice.
[0115] Table 6 shows the comparison of the target pathogen gene enrichment effect according to Example 1 of the present invention and Comparative Example 1. The present invention has obvious advantages in terms of HPV data ratio (HPV ratio), host data ratio (Human ratio), genome coverage (depth_100X), etc., especially through the novel host removal technology of the present invention, the host interference is significantly reduced, the target pathogen is greatly enriched, thereby significantly improving the coverage (depth_100X) and effective sequencing depth (AverageDepth) of the target genome.
[0116] Table 7 Comparison of the enrichment effect of Example 1 and Comparative Example 1
[0117]
[0118]
[0119] Example 2: Targeted enrichment of the Mycoplasma pneumoniae virus genome using the method of the present invention
[0120] The difference from Example 1 is that another pathogenic microorganism (Mycoplasma pneumoniae) is selected to verify the enrichment effect of the present application on clinical samples with low abundance (CT>30) and certain degradation. The specific experimental steps refer to Example 1. Five samples were tested respectively, and the test results are shown in Table 8.
[0121] Table 8 Targeted enrichment effect of Example 2 on Mycoplasma pneumoniae
[0122] Sample_ID MP-01 MP-02 MP-03 MP-04 MP-05 CT value 25.3 27.87 28.37 29.49 31.31 RawBase(e6) 22,127,168 33,048,098 15,459,892 10,645,850 6,294,200 MP Ratio 44.7 44.74 43.75 42.05 44.3 Human Ratio 43.11 53.95 50.77 56.29 47.25 AverageDepth 1730.8 3091.33 1344.03 999.83 518.57 Coverage 99.29% 99.29% 99.30% 99.28% 99.28% depth_4X 99.29% 99.29% 99.28% 99.28% 99.27% depth_10X 99.28% 99.29% 99.28% 99.27% 99.27% depth_30X 99.28% 99.28% 99.27% 99.27% 99.26 depth_100X 99.24% 99.27% 99.26% 99.24% 99.13%
[0123] As shown in Table 8, the enrichment method of the present invention can also be well used for targeted enrichment of the Mycoplasma pneumoniae virus genome. The full-length gene sequence (Coverage ≥ 99%) can be well enriched on different pathogenic microorganisms, and the coverage is highly uniform (depth_100X ≥ 99%). In addition, through the novel host removal method of the present invention, even in low-abundance (CT> 31) and degraded samples, the host data ratio (Human Ratio) can still be controlled at a relatively low level, achieving a good host removal and efficient enrichment of the full-length target pathogen genome.
[0124] The above describes the specific embodiments of the present invention. It should be understood that the present invention is not limited to the above specific embodiments, and those skilled in the art may make various modifications or variations within the scope of the claims, which do not affect the essence of the present invention.
Claims
1. A method for removing host genome from a sample to obtain pathogenic microorganism nucleic acid based on probe hybridization, characterized in that: include: S1. Design a host genome probe, which is a biotin-modified oligonucleotide complementary to the host genome nucleic acid base; S2, hybridizing the total nucleic acid extracted from the pathogen sample with the host genome probe of S1; S3, incubate with streptavidin and hybridization mixture; S4, using a magnetic device to aggregate the magnetic beads containing the host genome; S5. Take the supernatant to obtain nucleic acid that does not contain the host, which is the pathogenic microorganism nucleic acid.
2. The method according to claim 1, characterized in that The design method of the host genome probe in step S1 is: setting probes at intervals of 50-100 kb on the host genome to evenly cover the entire genome of the host.
3. The method according to claim 2, characterized in that The host is a human.
4. A sequencing method for efficiently enriching the full-length sequence of pathogenic microorganism genomes, characterized in that: include: S6. constructing a prelibrary of the pathogenic microorganism nucleic acid obtained according to the method of claim 1; S7, centrifugally concentrate the constructed pre-library, add biotin-modified pathogenic microorganism probes and hybridization mixture to perform hybridization incubation; S8, incubating the streptavidin magnetic beads with the hybridization mixture; S9, using a magnetic device to adsorb magnetic beads bound to pathogen genomes; S10, performing PCR amplification on the magnetic bead suspension to obtain an enriched microbial genome; S11. Perform library quality inspection and sequencing analysis.
5. The method according to claim 4, characterized in that The pathogenic microorganism probe in step S7 is designed based on the target pathogenic microorganism genome reference sequence using a highly shingled probe design method.
6. The method according to claim 4, characterized in that In step S7, the pathogenic microorganism probe and the prelibrary are hybridized and incubated at 60-70°C.
7. The method according to claim 4, characterized in that After the streptavidin in step S8 is mixed with the hybridization mixture, it is incubated at room temperature on a vertical rotator or a shaking metal bath.
8. The method according to claim 4, characterized in that Step S9 is specifically as follows: placing the magnetic bead mixture after incubation at room temperature in S8 on a magnetic rack, quickly centrifuging and discarding the supernatant, incubating and washing at 60-70°C, and then resuspending the magnetic beads with nuclease-free water, and the pathogen genome is adsorbed on the magnetic beads.
9. The method according to claim 4, characterized in that Step S10, after PCR amplification of the pathogen genome bound to the magnetic beads, also includes washing the magnetic beads with ethanol, eluting the pathogen genome from the magnetic beads with a buffer solution, and centrifuging on a magnetic stand, with the pathogen genome being located in the supernatant.
